Welcome to our dedicated page for Ainos SEC filings (Ticker: AIMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ainos, Inc. filings document operating results, material agreements, governance matters, and the securities structure of a Nasdaq-listed company with AIMD common stock and AIMDW warrants. Form 8-K reports cover annual and quarterly financial results, AI Nose commercialization updates, distribution rights for AINOS AI Nose products and services, and amendments to product-development and patent-use arrangements.
The company’s proxy materials disclose director elections, shareholder voting matters, compensation information, and governance procedures. Its filings also describe relationships involving Taiwan Carbon Nano Technology Corporation and Ainos KY, including control and voting-power matters relevant to the company’s corporate governance and development agreements.
Ainos, Inc. (AIMD) reported an insider equity award for its CEO, President and Chairman, Chun-Hsien Tsai. On November 25, 2025, he acquired 80,000 shares of common stock at a reported price of $2.10 per share, classified as an acquisition of non-derivative securities. Following this transaction, he beneficially owned 410,372 shares of Ainos common stock directly.
The filing also shows related derivative activity, where 80,000 restricted stock units (RSUs) were converted into the same number of common shares and the RSU balance went to zero. The company notes these 80,000 shares were granted and vested as special stock awards on November 25, 2025, after having been approved by Ainos stockholders on November 7, 2025.
Ainos, Inc. (AIMD) director received a special stock award that resulted in the acquisition of 80,000 shares of common stock on November 25, 2025 at a price of $2.10 per share. These shares were granted and fully vested as special stock awards that had been approved by Ainos stockholders on November 7, 2025. Following this transaction, the reporting person now beneficially owns 365,707 shares of Ainos common stock directly.
Ainos, Inc. (AIMD) reported an insider equity award to one of its directors. On November 25, 2025, the reporting person received a grant of 50,000 shares of common stock as special stock awards, which were granted and vested on the same date at a reported price of $2.10 per share. These awards had been approved by Ainos stockholders on November 7, 2025.
Following this transaction, the director beneficially owns 101,546 shares of Ainos common stock in direct ownership. The filing also shows related movements in derivative securities (RSUs) that correspond to the 50,000 underlying common shares, with the RSU position moving to zero after conversion into common stock.
Ainos, Inc. (AIMD) reported an insider equity transaction by a director. On 11/25/2025, the reporting person received 50,000 shares of common stock as special stock awards at a reported price of $2.10 per share, increasing their directly held stake to 90,880 shares after the transaction. These 50,000 shares were granted and vested as part of special stock awards that had been approved by Ainos stockholders on 11/7/2025. The filing also shows related movements in restricted stock units and their conversion into common stock.
Ainos, Inc. (AIMD) reported that its Chief Financial Officer received a special stock award. On November 25, 2025, the CFO acquired 20,000 shares of common stock at a price of $2.10 per share, following the vesting of a restricted stock unit grant reported in the derivative table. After this transaction, the CFO beneficially owns 75,275 shares of Ainos common stock directly. The company’s stockholders had previously approved these special stock awards on November 7, 2025.
Ainos, Inc. (AIMD) reported an insider equity transaction by a director. On November 25, 2025, the director received 50,000 shares of common stock as special stock awards, which were granted and vested on that date. The awards were previously approved by Ainos stockholders on November 7, 2025.
The filing shows the 50,000 shares were acquired at a price of $2.10 per share, increasing the director’s directly held stake to 90,880 shares of Ainos common stock following the transaction. The Form 4 also reflects related movements in restricted stock units (RSUs) that converted into the same number of common shares.
Ainos, Inc. (AIMD) reported an insider equity award for a director. On November 25, 2025, the reporting person, serving as a director, acquired 80,000 shares of common stock at $2.10 per share, following the vesting of 80,000 restricted stock units (RSUs) granted as special stock awards. After this transaction, the director beneficially owned 356,999 shares of Ainos common stock in direct ownership. The filing notes that these special stock awards were approved by Ainos stockholders on November 7, 2025.
Ainos, Inc. (AIMD) filed its Q3 2025 10‑Q, reporting continued operating losses with limited cash. Nine‑month revenue was $113,037, up from $20,729, driven mainly by VOC sensing co‑development and modest VELDONA Pet sales. Net loss was $10,302,714, and operating loss reached $9,692,751. Cash and cash equivalents were $1,128,217 at September 30, 2025. The company disclosed “substantial doubt” about its ability to continue as a going concern.
To support liquidity, Ainos used its at‑the‑market program with H.C. Wainwright, selling 674,867 shares for $1,852,895 in net proceeds through September 30 and an additional 18,837 shares for $68,151 from October 1 to November 13. Shares outstanding were 4,793,797 as of September 30 and 4,812,634 as of November 13, 2025, following a 1‑for‑5 reverse split effective June 30. R&D expenses were $5,626,514 and SG&A $4,159,627 for the first nine months, reflecting ongoing investment in AI Nose, POCT, and VELDONA development while the business advances pilot deployments and partnerships.
Ainos, Inc. (AIMD) filed an 8-K detailing shareholder voting results and the furnishing of a press release with results for the quarter ended September 30, 2025.
At the November 7 Annual Meeting, a quorum was present with 3,226,793 votes, representing approximately 67.63% of outstanding votes. Seven directors were elected with vote support near or above 98%. Shareholders approved the ratification of YCM CPA INC. as independent auditor for the fiscal year ending December 31, 2025.
Shareholders also approved the reservation of up to 950,000 shares of common stock as special stock awards not issued under the 2023 Stock Incentive Plan. As of the September 17 record date, 4,771,184 common shares were outstanding and entitled to vote. The company furnished, but did not file, a press release announcing quarterly results as Exhibit 99.1.
Ainos, Inc. entered a Fourth Addendum to its Product Development Agreement with Taiwan Carbon Nano Technology Corporation (TCNT). The amendment sets a fee for the exclusive use of patents of $50,000 per month plus 5% sales tax for a two-year period starting October 16, 2025, replacing the prior one-year period starting October 16, 2024.
TCNT controls the company through its majority interest in Ainos KY and direct ownership, with Ainos KY holding majority voting power via voting agreements. The parties may negotiate payment terms and subsequent licensing methods after the two-year period. An English translation of the Fourth Addendum is filed as Exhibit 10.1.